On July 3, XtalPi Holdings rose 5.35% in regular trading, trading at HKD 7.86/share, with turnover of HKD 356 million.

On the news front, the company granted approximately 34.98 million share options and 8.68 million restricted share units on July 2 at an exercise price of HKD 7.48, signaling management confidence. This adds to a series of recent positive developments: a strategic AI drug discovery partnership with an international pharmaceutical company valued at over $400 million targeting GPCR oral small-molecule therapies, a $100 million share buyback plan in continuous execution since June 10, and the successful deployment of an AI autonomous experiment workstation at Sinopec marking substantive expansion into materials science.

The broader CXO sector continued its recovery, with Wuxi XDC up 6.21%, Wuxi Biologics up 4.74%, GenScript Biotech up 3.73%, and Wuxi AppTec up 2.68%, providing sector-level tailwinds to the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)